

INVESTOR WEBINAR

Perth, Australia; 3 September 2025 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is please to invite shareholders and interested investors to attend an upcoming investor webinar following the release of the Company's recent Phase 2 Acute Ischaemic Stroke Trial Topline Data results.

Investor Webinar 10.30am AEST Wednesday 3 September, 2025

You are invited to register using the link below:

https://us06web.zoom.us/webinar/register/WN_m4Gpu9IDQa2SlZCdpNUxaQ

Participants may submit questions at registration or during the session

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has recently completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica is now conducting a Phase 2 clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.